Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Abstracto

Possibility for Allergy Immunotherapy with Long Synthetic Peptide of Bet V1

Motoharu Uehara*,Hiroyuki Hirai

In allergy immunotherapy (AIT) using peptides, although the choice of T-cell epitope in consideration of the HLA type is important, application to all HLA types is difficult. We recently devised a new method to address this problem in AIT for white birch pollinosis, using long-chain synthetic peptides by dividing the sequence of Bet v1a, the major allergen in white birch pollen, into three peptides that overlap by 10 amino acid residues. Theoretically, these peptides contain all possible T-cell epitopes for any HLA type. Further, these peptides show weak allergenicity and are considered less prone to cause anaphylaxis because the three-dimensional structures differ significantly from the native Bet v1a. The combination of these three peptides of Bet v1a appears to provide an effective, safe form of AIT for white birch pollinosis. This method may thus be applicable to other allergens.